Strategic Advisory Board
We are supported by international experts and key opinion leaders to help guide our scientific strategy and build academic networks to enable access to cutting-edge research from world-renowned laboratories to strengthen our drug discovery programs.
Dr Jürgen Moll
Dr Jürgen Moll, PhD is the co-founder and CSO of iDEL Therapeutics developing a synthetic shuttle for cytosolic drug delivery and serves in the SAB of several companies, e.g. PROTAi and GORDION. Until Oct. 2025, he was CSO of Tesselate Bio responsible for strategically building our pipeline. He has >25y experience in the biotechnology and pharma industry, having served in senior role at Sanofi, Boehringer Ingelheim, Pfizer and Nerviano Medical Sciences.
Professor Hilda Pickett
Prof. Hilda Pickett, PhD is a co-founder of Tessellate Bio and is Head of the Telomere Length Regulation Unit at Children’s Medical Research Institute (CMRI), and Conjoint Professor at the University of Sydney.
Professor Claus Azzalin
Prof. Claus Azzalin, PhD is a co-founder of Tessellate Bio and group leader at Instituto de Medicina Molecular (iMM), Lisbon, and a Professor at the University of Lisbon, Portugal.
Professor René Bernards
Prof. René Bernards, PhD is Group Leader at the Netherlands Cancer Institute (NKI), Amsterdam and Professor of Molecular Carcinogenesis at Utrecht University, The Netherlands.
Professor Christopher Lord
Prof. Christopher Lord, DPhil is Deputy Head of Division, Deputy Director of the Breast Cancer Now Toby Robins Research Centre, Group Leader of the CRUK Gene Function Laboratory and Professor of Cancer Genomics at the Institute of Cancer Research (ICR), London, United Kingdom.
Professor George Demetri
Prof. George D. Demetri, MD is a Professor of Medicine at Harvard Medical School, Director at the Center for Sarcoma and Bone Oncology at the Dana-Farber Cancer Institute (DFCI), and Quick Family Chair, Medical Oncology at the DFCI in Boston, United States.
Professor Giulio Draetta
Prof. Giulio Draetta, MD PhD is Chief Strategy Offcier of Orionis Biosciences, a clinical-stage life sciences company pioneering the development of novel precision medicines. Before, he was Chief Scientific Officer, Sewell Family Distinguished University Chair and Professor of Genomic Medicine at the University of Texas MD Anderson Cancer Center.
Professor Timothy Yap
Prof. Timothy Yap, MD PhD FRCP is Professor in the Department for Investigational Cancer Therapeutics and the Department of Thoracic/Head and Neck Medical Oncology, as well as Vice President, Head of Clinical Development in the Therapeutics Discovery Division and Associate Director of Translational Research in the Institute for Personalized Cancer Therapy.
Professor Sandra Strauss
Prof. Sandra Strauss, MBBS FRCP PhD is a Professor of Medical and Teenage Young Adult Cancer (TYA) and an honorary consultant medical oncologist at University College London Hospital NHS Trust.
Professor Julie George
Prof. Julie George, Dr. rer. nat. is a Professor for Molecular Head and Neck Oncology and Principal Investigator at the Department of Translational Genomics of the University of Cologne.
Professor Martin Reck
Martin Reck, MD, PhD is the Head of Thoracic Oncology at the LungenClinic Grosshansdorf, Germany.
He is a globally recognized key opinion leader in thoracic oncology, having served as a principal investigator for multiple landmark clinical trials that have established modern chemoimmunotherapy and targeted treatments for Small Cell Lung Cancer. His extensive research focuses on innovative thoracic cancer therapeutics and the development of predictive biomarkers to personalize patient care.